Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting CPT1A enhances metabolic therapy in human melanoma cells with the BRAF V600E mutation.

The international journal of biochemistry & cell biology - 1 Dec 2016

Sung Gi-Jun, Choi Hyo-Kyoung, Kwak Sungmin, Song Ji-Hye, Ko Hyeonseok, Yoon Ho-Geun, Kang Hee-Bum, Choi Kyung-Chul

Abstract excerpt

Cancer cells are characterized by altered metabolic processes. Recent evidence of metabolic alterations has indicated that the fatty acid oxidation (FAO) pathway is used as a carbon source for anabolic processes in some tumors, thus making this pathway a potential target for therapy. The carnitine palmitoyltransferase (CPT; EC 2.3.1.21) enzyme transfers long-chain fatty acids from the cytosol to the mitochondrial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Carnitine O-Palmitoyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Transformation, Neoplastic

Share to Gene Knockdown Techniques

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Oxidation-Reduction

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 27793752
DOI: 10.1016/j.biocel.2016.10.019

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting CPT1A enhances metabolic therapy in human melanoma cells with the BRAF V600E mutation.PMID 27793752Read ↗

Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanomaSemantic proximity Read ↗

Melanoma Metabolism: Molecular Mechanisms and Therapeutic Implications in Cutaneous OncologySemantic proximity Read ↗

Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.Semantic proximity Read ↗

New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.Semantic proximity Read ↗

Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma.Semantic proximity Read ↗

Altered Expression of Carnitine Palmitoyl Transferase 1C (CPT1C) is Related to the Aggressive Pathobiology of Glioblastoma: A Potential Metabolic VulnerabilitySemantic proximity Read ↗

Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review.Semantic proximity Read ↗

Impact of the sphingolipid metabolizing enzyme β-galactosylceramidase on mitochondrial sphingolipid profile and energetic metabolism in human melanoma cellsSemantic proximity Read ↗

Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.Semantic proximity Read ↗

Simvastatin reprograms lipid metabolism in B16.F10 melanoma cells to favor an early resistant phenotype.Semantic proximity Read ↗

Cancer metabolism: fatty acid oxidation in the limelight.Semantic proximity Read ↗

BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.